Zhang F, et al. – This study offers an update on the use of Renin Angiotensin Aldosterone System (RAAS) inhibitors as dual therapy or monotherapy in different stages of kidney disease. Evidence from clinical studies was demonstrative of a preventive role of RAAS inhibitors in both early and end stages of kidney disease as these agents prevent proteinuria, kidney fibrosis and slow decline of renal function. Although these agents were found to be more effective when used in combination than monotherapy, the reported incidence of adverse events was higher with combined use of RAAS inhibitors.